dc.contributor.author | Chung, Michael H | |
dc.contributor.author | Etyang, Anthony | |
dc.contributor.author | Thiga, Joan W | |
dc.contributor.author | Benki-Nugent, Sarah F | |
dc.contributor.author | Kohler, Pamela K | |
dc.contributor.author | John-Stewart, Grace C | |
dc.contributor.author | Njoroge, Julia | |
dc.contributor.author | McGrath, Christine J | |
dc.date.accessioned | 2013-06-18T12:40:05Z | |
dc.date.available | 2013-06-18T12:40:05Z | |
dc.date.issued | 2012-06 | |
dc.identifier.citation | Journal of NeuroVirology June 2012, Volume 18, Issue 3, pp 200-204 | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/35655 | |
dc.description.abstract | The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described. We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4T-based and 269 (15 %) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n = 236) among d4T users and 6.9 (n = 7) among ZDV users (P = 0.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P = 0.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens. | en |
dc.language.iso | en | en |
dc.title | Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya | en |
dc.type | Article | en |
local.publisher | Department of Plant Science and Crop Protection | en |